Clinical Trials
2,551 trialsOPAL
iOMEDICO AG
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
ASPEN-09-03
ALX Oncology Inc.
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSenseĀ® Cryoablation (ChoICE Trial)
IceCure Medical Ltd.
FLAMINGO-01
Greenwich LifeSciences, Inc.
ELECTRA
Stemline Therapeutics, Inc.
PIKALO-1
Eli Lilly and Company
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
REMERGE
Hoffmann-La Roche
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
BeOne Medicines
panSOHO
Bayer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
FiREBOLT
Eli Lilly and Company
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
DARE
Criterium, Inc.
RAINFOL-01
Genmab
Adjuvant WIDER
Novartis
INAVO123
Hoffmann-La Roche
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
OMNIRAY
Eli Lilly and Company
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech, Inc.
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
TerSera Therapeutics LLC
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Cellectar Biosciences, Inc.
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Pfizer
EPIK-B5
Novartis
CERTIS1
AstraZeneca
Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
Pfizer
A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)
Pfizer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc.
HERMIA
Abscint NV/SA
ROSIE
Pfizer
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
Shandong Suncadia Medicine Co., Ltd.
HLD-0117
Halda Therapeutics OpCo, Inc.
ROSE
Ipsen
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis
CASCADE
AstraZeneca
CAROLEEN
Novartis
DELUMA
Delcath Systems Inc.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
IMPACT
Lumicell, Inc.
INAVO122
Hoffmann-La Roche
Pangeia-2
AstraZeneca
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics Inc.